Headquartered in The Heights, Weybridge Fiscal year ends December NYSE: HLN haleon.com
Haleon plc (LSE/NYSE: HLN) is a consumer health company solely focused on everyday health products. The company operates across six major product categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. Its portfolio includes well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, which are trusted by more than one billion consumers globally and recommended by health professionals worldwide. Haleon was demerged from GSK and listed as an independent public company on both the London Stock Exchange and the New York Stock Exchange. Updated
Goldman Sachs handpicks European stocks with the highest conviction for outperformance, and four of October's top selections carry a benefit most growth-focused investors overlook entirely.
Haleon plc (LSE/NYSE: HLN) is a consumer health company solely focused on everyday health products. The company operates across six major product categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other.
24/7 Wall St.'s 12-month price target for HLN is $10.26, rated Hold. The Wall Street consensus target is $11.93. HLN price prediction →
